Literature DB >> 16434173

Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma.

Aissa Imen1, Khattab Amal, Zendah Ines, El Farhati Sameh, El Mekki Fethi, Ghedira Habib.   

Abstract

Gemcitabine considered is to be a well-tolerated cytostatic drug with little known side effects. Cutaneous reactions are well known but still rarely reported. We report the case of a 75-year-old man with stage IV non-small-cell lung carcinoma treated with combination of gemcitabine 1000 mg/m2 and cisplatin 75 mg/m2 repeated every 28 days, who developed bilateral cutaneous bullous lesions of lower limbs following gemcitabine administration. Histopathologic examination did not show any toxidermy aspect and there was not any sign of immunoglobulin deposit in direct immunofluorescence test. Chemotherapy was stopped and lesions disappeared without any treatment. Even delayed with regard to gemcitabine administration, the causal relationship of gemcitabine treatment with skin reaction is possible according to the Naranjo probability scale. Pathologists should be aware of this kind of side effect in managing chemotherapy drugs and report any dermatologic reactions in order to identify the cause of toxicity and avoid a misdiagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434173     DOI: 10.1016/j.rmed.2005.11.027

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  1 in total

1.  Gemcitabine-induced skin necrosis.

Authors:  Maria Monica Haydock; Saroj Sigdel; Toni Pacioles
Journal:  SAGE Open Med Case Rep       Date:  2018-10-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.